WHO issues new clinical advice on treating COVID-19 patients

Send a link to a friend  Share

[January 26, 2021]  GENEVA (Reuters) - The World Health Organization (WHO) issued fresh clinical advice on Tuesday for treating COVID-19 patients, including those displaying persistent symptoms after recovery, and also said it advised using low-dose anti-coagulants to prevent blood clots.

"The other things in the guidance that are new are that COVID-19 patients at home should have the use of pulse oximetry, that's measuring the oxygen levels, so you can identify whether somewhat at home is deteriorating and would be better off having hospital care," WHO spokeswoman Margaret Harris told a U.N. briefing in Geneva.

The WHO advised clinicians to put patients into the awake prone position, on their front, shown to improve the oxygen flow, she said.

"Also we recommend, we suggest the use, of low-dose anti-coagulents to prevent blood clots forming in blood vessels. We suggest the use of lower doses rather than higher doses because higher doses may lead to other problems," Harris said.

She added that a WHO-led team of independent experts, currently in the central Chinese city of Wuhan where the first human cases were detected in December 2019, is due to leave quarantine in the next two days to pursue its work with Chinese researchers on the virus origins.

[to top of second column]

She declined to commment on reports of delays in roll-out of vaccines in the European Union. She said she had no specific data and the WHO's priority was for health workers in all countries to be vaccinated in the first 100 days of the year.

AstraZeneca , which developed its shot with Oxford University, told the EU on Friday it could not meet agreed supply targets up to the end of March.

(Reporting by Stephanie Nebehay and Emma Farge)

[© 2021 Thomson Reuters. All rights reserved.]

Copyright 2021 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content

 

Back to top